ANIP
ANI Pharmaceuticals, Inc.
$72.29
Platform & Compounding FCF
85%
Two-stage FCF DCF
Strong
·
Conviction
Undervalued
Trading 68.0% below fair value
You pay
$72.29
Bear
$133.18
Fair
$226.07
Bull
$335.82
Bear
$133.18
+84.2%
10% stage 1 growth, 11% discount
Fair
$226.07
+212.7%
17% stage 1 growth, 11% discount
Bull
$335.82
+364.5%
23% stage 1 growth, 11% discount
Adjust Assumptions
17.4%
11.0%
3.0%
Key Value Driver
FCF growth rate (17% base case)
Terminal Value % of EV
45%
Implied Market Multiple
12.2x
Market is pricing in (growth)
2.3%
vs 17.4% base
Analyst Consensus (External Reference)
Never blended into the bear/base/bull estimates above.
Average Target (10 analysts)
$99.50
Divergence from AlphaVal
127%
Summary
Using a two-stage FCF DCF with 17% growth decelerating over 15 years, discounted at 11%, the base-case intrinsic value is $226.07 per share.
Warnings
Stock-based employee pay equals 48% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.
Wall Street's average price target is $99.50 (from 10 analysts). Our estimate is 127% above the consensus -- consider that gap carefully.
Key Risks
- P/E alone misleads — earnings depressed by growth investment
- Cyclical or commodity businesses may be misclassified as platforms
- Terminal value dominance suggests sensitivity to long-run assumptions